Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | AGER | Q15109 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567095 | 1.00 | KMT2A (0.53) | KMT2AAGERALDH1A1HDAC2TAOK1 | |
| SCHEMBL30567110 | 0.87 | MAPK1 (0.53) | KMT2AAGERALDH1A1HDAC2TAOK1 | |
| SCHEMBL25387819 | 0.87 | MAPK1 (0.53) | KMT2AAGERALDH1A1HDAC2TAOK1 | |
| SCHEMBL31256612 | 0.86 | ALDH1A1 (0.54) | KMT2AALDH1A1TAOK1PPARGMEN1 | |
| SCHEMBL25386145 | 0.86 | ALDH1A1 (0.54) | KMT2AALDH1A1TAOK1PPARGMEN1 | |
| SCHEMBL25386759 | 0.85 | MAPK1 (0.46) | KMT2AAGERALDH1A1HDAC2TAOK1 | |
| SCHEMBL30567121 | 0.85 | MAPK1 (0.46) | KMT2AAGERALDH1A1HDAC2TAOK1 | |
| SCHEMBL25386852 | 0.83 | L3MBTL1 (0.50) | KMT2AAGERALDH1A1TAOK1PPARG | |
| SCHEMBL25386208 | 0.82 | RXFP1 (0.47) | KMT2AALDH1A1HDAC2TAOK1PPARG | |
| SCHEMBL30567126 | 0.82 | RXFP1 (0.47) | KMT2AALDH1A1HDAC2TAOK1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171404-A1 | PCNA INHIBITORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2025-05-29 | — | — | US | disclosed |
| WO-2023172880-A2 | PCNA INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172880-A2 | PCNA INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171404-A1 | PCNA INHIBITORS AND USES THEREOF | PCNA, MKI67, PCLAF | KMT2A 1014/4885AGER 4132/4885ALDH1A1 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.